GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eusol Biotech Co Ltd (ROCO:6652) » Definitions » Net Income From Continuing Operations

Eusol Biotech Co (ROCO:6652) Net Income From Continuing Operations : NT$-32.92 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eusol Biotech Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Eusol Biotech Co's net income from continuing operations for the six months ended in Dec. 2024 was NT$-14.82 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-32.92 Mil.

Eusol Biotech Co Net Income From Continuing Operations Historical Data

The historical data trend for Eusol Biotech Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eusol Biotech Co Net Income From Continuing Operations Chart

Eusol Biotech Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -113.50 -123.58 -12.29 -49.12 -32.92

Eusol Biotech Co Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.86 -18.04 -31.08 -18.09 -14.82

Eusol Biotech Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-32.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eusol Biotech Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eusol Biotech Co Ltd (ROCO:6652) » Definitions » Net Income From Continuing Operations
Comparable Companies
ROCO:6662 ROCO:6999 ROCO:6917 ROCO:6709 ROCO:6610 ROCO:4192 ROCO:6549 ROCO:6827 ROCO:6814 ROCO:7725 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No.135, Section 3, Minsheng East Road, 6th Floor, Songshan District, Taipei, TWN, 10546
Website
https://www.eusol.com.tw
Eusol Biotech Co Ltd is a Taiwan based company that invests in developing new drugs to fulfill unmet medical needs. Its pipeline products include ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids; and SM-1, a 3-in-1 capsule containing 3 commercial drugs with the sedative effect.

Eusol Biotech Co Headlines

No Headlines